Investment Rating - The industry investment rating is maintained at "Overweight" [7] Core Insights - The report highlights the continuous upgrading of policies in the Heilongjiang biomanufacturing industry, focusing on innovative traditional Chinese medicine and innovative medical devices [4] - The report emphasizes the significant revisions to the Drug Administration Law, which provides institutional support for pharmaceutical innovation and high-quality development [4] - The report identifies three major transformations in China's innovative drug business development (BD) in 2026: technology output combined with product authorization, platform cooperation, and global parallel innovation [8] Summary by Sections Industry Performance - Over the past 12 months, the industry has shown a relative return of -7.06% compared to the CSI 300 index, with an absolute return of 11.53% [3] Investment Highlights - The report notes that BD transactions in the pharmaceutical sector are focused on unmet clinical needs, technological differentiation, and global value [6] - Key areas of focus include oncology therapies such as dual antibodies, ADCs, and TCE combinations, with significant financial agreements highlighted, such as a $650 million upfront payment for a PD-1/VEGF dual antibody [6] - The metabolic disease sector is centered on long-acting GLP-1 and small nucleic acid precision therapies, with notable collaborations resulting in substantial upfront payments and potential total amounts [6] Company-Specific Developments - Companies like Andover Pharmaceuticals and Frontier Biotech have secured significant collaborations with major pharmaceutical firms, indicating a trend towards platform-based cooperation and technology output [7] - Specific collaborations include a $1.05 billion deal for a CTLA-4 inhibitor and a $400 million agreement for small nucleic acid drugs, showcasing the growing interest in innovative therapies [7] - The report suggests monitoring companies such as Rebio Biotech and WuXi AppTec for their advancements in small nucleic acids and platform capabilities [8]

Core Viewpoint - Haitong International reports that the main business revenue and profit of CSPC Pharmaceutical Group (01093) have bottomed out, with expectations to return to an upward cycle by 2026 and benefit from the launch of innovative oncology and metabolic products starting in 2027 [1] Group 1: Revenue and Profit Outlook - The potential milestone revenue for CSPC Pharmaceutical Group is estimated at $5.8 billion (approximately RMB 40.6 billion), which is expected to gradually enhance the company's profits over the next 3-5 years [1] - The firm believes that upfront payments and milestone revenues will provide sustainable recurring income for the company, leading to an upward revision of the revenue forecast for authorized products post-2027 [1] Group 2: R&D and Collaboration - CSPC Pharmaceutical Group has achieved seven external collaboration deals in the past two years, with total upfront payments of $1.71 billion and potential milestone revenues exceeding $30 billion [2] - The company has partnered with AstraZeneca three times, highlighting its R&D platform's global influence and value [2] - The firm is optimistic about CSPC's ability to generate regular income through milestone sales and net revenue sharing throughout the drug lifecycle [2] Group 3: Pipeline and Technology - CSPC's small nucleic acid platform has a broad layout, targeting popular liver delivery points such as PCSK9, AGT, and ANGPTL3, and is ahead of domestic peers in development [3] - The company has applied for patents related to lipid delivery and specific siRNA treatments, indicating potential advancements in neurological and ocular delivery technologies [3] - The SYS6010 (EGFR-ADC) has accumulated clinical data from over a thousand patients, showing potential for best-in-class efficacy and safety [4] Group 4: Clinical Developments - The company has initiated a Phase III clinical trial for SYS6010 in China for first-line treatment of non-small cell lung cancer (NSCLC) and plans to advance global Phase III trials [4] - CSPC's in vivo CAR-T product, SYS6055, has received clinical approval in China, representing the first in vivo CAR-T product approved domestically, with potential advantages in cost and accessibility [4] Group 5: Financial Projections - The firm has adjusted revenue forecasts for FY25, FY26, and FY27 to RMB 26.7 billion, 28.9 billion, and 30.6 billion respectively, reflecting changes in the recognition of upfront payments [5] - The net profit forecasts for FY25, FY26, and FY27 have been revised to RMB 4.4 billion, 4.6 billion, and 5.3 billion respectively [6]

Core Viewpoint - Haitong International reports that the main business revenue and profit of CSPC Pharmaceutical Group (01093) have bottomed out, with expectations of returning to an upward cycle by 2026 and benefiting from the launch of oncology and metabolic innovative products starting in 2027 [1] Group 1: Financial Projections - The potential milestone revenue for CSPC Pharmaceutical Group is estimated at $5.8 billion (approximately RMB 40.6 billion), which is expected to enhance the company's profits over the next 3-5 years [1] - Haitong International has adjusted the revenue forecasts for FY25, FY26, and FY27 to RMB 26.7 billion, RMB 28.9 billion, and RMB 30.6 billion respectively [5] - The net profit forecasts for FY25, FY26, and FY27 have been adjusted to RMB 4.4 billion, RMB 4.6 billion, and RMB 5.3 billion respectively [6] Group 2: Research and Development Capabilities - CSPC Pharmaceutical Group has completed seven external cooperation transactions in the past two years, with total upfront payments of $1.71 billion and potential milestone amounts exceeding $30 billion [1] - The company has established a strong research and development platform, evidenced by collaborations with AstraZeneca, indicating its global influence and value [1] - The company is recognized for its small nucleic acid platform, which covers popular liver delivery targets and is ahead of domestic peers in development [2] Group 3: Product Pipeline and Market Potential - The SYS6010 (EGFR-ADC) has accumulated clinical data from over a thousand patients, showing potential as a best-in-class product [3] - The company has initiated a Phase III clinical trial for SYS6010 in China and plans to advance global Phase III trials within the year [3] - CSPC has received the first clinical approval in China for its in vivo CAR-T product, SYS6055, which is expected to have advantages in cost, accessibility, and immediacy compared to traditional CAR-T products [4]

Investment Rating - The report maintains an "OUTPERFORM" rating for CSPC Pharmaceutical Group with a target price of HK$13.07, while the current price is HK$10.06 [2]. Core Insights - CSPC Pharmaceutical Group has achieved multiple recognitions from multinational corporations (MNCs) and has made significant progress in innovation transformation, indicating a highly anticipated platform value [1]. - The company has completed seven external collaboration transactions with a total upfront payment of US$1.71 billion and potential milestone payments exceeding US$30 billion, which are expected to enhance the company's profits over the next 3-5 years [3][10][11]. - The report highlights the company's strong research and development capabilities, particularly in cell therapy, ADC, siRNA, and mRNA technologies, which are expected to yield external licensing opportunities [3][4][5]. Financial Summary - Revenue projections for FY25, FY26, and FY27 are adjusted to RMB 267 billion, RMB 289 billion, and RMB 306 billion respectively, with net profit estimates revised to RMB 44 billion, RMB 46 billion, and RMB 53 billion [8]. - The company is expected to return to a growth cycle in 2026, benefiting from the commercialization of innovative oncology and metabolic products [8]. Research and Development Highlights - CSPC's small nucleic acid platform is positioned among the top tier of domestic pharmaceutical companies, with a broad pipeline targeting liver delivery for conditions such as hyperlipidemia and hypertension [4][31]. - The company has received clinical approval for its in vivo CAR-T product, SYS6055, marking a significant advancement in cell therapy within China [7][26]. - SYS6010, an EGFR ADC, has shown promising clinical data, with ongoing trials in both China and the US, indicating strong potential for international market entry [17][19][23]. Collaboration and Licensing Opportunities - The report emphasizes the importance of CSPC's collaborations with leading pharmaceutical companies like AstraZeneca and Madrigal, which are expected to contribute to sustainable revenue through milestone and royalty payments [11][12][13]. - CSPC's innovative platforms, including its AI drug discovery platform, are anticipated to enhance its competitive edge in the global market [11][13]. Pipeline Overview - CSPC has a diverse pipeline in oncology, with several candidates in various stages of clinical development, including dual antibodies and ADCs, which are expected to compete effectively on a global scale [14][15]. - The report outlines the company's strategic focus on advancing its clinical trials and expanding its product offerings in both domestic and international markets [19][24].

Summary of Key Points from the Conference Call Industry Overview - The conference call primarily discusses the **pharmaceutical industry** in China, focusing on **business development (BD)** activities and **medical reform policies** [1][3][7]. Core Insights and Arguments - **BD Transactions**: As of February 15, 2026, the total upfront payment for BD transactions reached **$3 billion**, with an overall volume of **$49 billion**, significantly surpassing levels from 2025, indicating a substantial increase in BD activities for 2026 [1][4]. - **Notable Collaborations**: - **Shijiazhuang Pharmaceutical Group** partnered with **AstraZeneca** for a deal worth **$18.5 billion**, marking a recent high in China's innovation drug licensing [1][4]. - **Qin Hao Pharmaceutical** licensed its targeted small molecule drug **JX31** to **Gilead**, confirming the CRO industry's positive outlook [3]. - **Regen Bio** and **Metagene** entered a deal for six small nucleic acid drugs, with a total upfront payment of **$60 million** and potential milestone payments of **$4.4 billion** [4]. - **Clinical Trials**: Chinese companies are advancing in overseas R&D, with **Shijiazhuang Pharmaceutical** initiating Phase III trials for its **SYH2053** drug targeting high cholesterol and high triglycerides [5][6]. Medical Reform Policies - The revision of the **Basic Directory Management Measures** emphasizes alignment with procurement and medical insurance policies, with adjustments occurring approximately every three years, potentially accelerating the inclusion of procurement in the basic directory [7]. - The **collective procurement** process has shown a **93% selection rate**, indicating a more moderate policy direction focusing on quality rather than aggressive competition [7][8]. Key Trends in Drug Procurement - The recent drug procurement renewals have a **98% coverage rate**, with a focus on matching clinical needs and supplier quality, indicating a rational approach to procurement [8]. Company-Specific Developments - **Hansen Pharmaceutical** received EU approval for **Amivantamab**, targeting advanced non-small cell lung cancer [9]. - **Frontier Bio**'s collaboration with **GSK** for small nucleic acids is significant, with an upfront payment of **$40 million** and milestone payments of **$963 million**, highlighting the value of early research capabilities [10]. Impact of Tariffs and Regulations - The recent ruling against Trump's tariffs may benefit companies previously affected by fentanyl tariffs, such as **Jin You Co.** [11]. - The CRO industry is expected to see a turning point in 2026, with positive indicators from major conferences and performance forecasts [12]. Noteworthy Companies in Robotics and Medical Devices - Companies like **MicroPort Robotics**, **Jingfeng Medical**, and **Tianzhihang** are leading in the surgical robotics sector, with **MicroPort** achieving over **200 orders** across **50 countries** [13]. - The **medical device sector** is also seeing growth in areas like brain-computer interfaces and AI medical applications, with companies like **Borycon** and **Zhiruan Medical** gaining attention [14][18]. Performance Expectations - **Lepu Medical** and **Yingke Medical** are expected to see around **50% growth** in their respective sectors, driven by increased demand and market recovery [15][16]. - **Bai Ao Sai Tu** is projected to achieve over **$400 million** in profits from its CRO and model animal business, with a total valuation of approximately **$20 billion** [20]. Recommendations for Investment - The report suggests focusing on companies with strong beta attributes and clear growth logic, such as **Bai Ao Sai Tu** and **Sen Song** [22]. - **Aopu Mai** is also highlighted for its potential growth, with a projected market value of around **$8 billion** [21]. This summary encapsulates the key points discussed in the conference call, providing insights into the pharmaceutical industry's current landscape and future opportunities.

Group 1 - The Hong Kong Dividend ETF (ICBC, 159691) closed at a 2.18% increase with a trading volume of 289 million yuan on February 24 [1] - The fund was established on March 30, 2023, with an annual management fee of 0.45% and a custody fee of 0.07% [1] - As of February 13, 2025, the fund's latest share count was 6.21 billion shares, with a total size of 8.643 billion yuan, reflecting a 4.90% decrease in shares and a 2.46% increase in size year-to-date [1] Group 2 - The current fund managers are Zhao Xu and Jiao Wenlong, both managing the fund since February 5, 2026, with a return of 0.99% during their tenure [2] - The top holdings of the fund include China National Offshore Oil Corporation (14.55%), China Shenhua Energy (9.65%), and China Pacific Insurance (8.90%), among others [2] - The fund's recent trading activity shows a cumulative trading amount of 6.707 billion yuan over the last 20 trading days, with an average daily trading amount of 335 million yuan [1]

Core Insights - The Chinese innovative pharmaceutical industry is transitioning from "catching up" to "keeping pace" and even "leading" on a global scale, with a significant increase in business development (BD) transactions indicating enhanced international competitiveness [2][11][12] - The trend of BD transactions is accelerating, with record-breaking transaction sizes and optimized structures, marking a shift from single product licensing to platform-based and systematic collaborations [2][11] - The demand for Chinese innovative assets from global pharmaceutical companies is increasing due to challenges such as patent cliffs and declining R&D returns, creating a supportive environment for the high activity in the BD market [12] Recent Market Performance and BD Transaction Analysis - In January 2026, the pharmaceutical and biotechnology sector outperformed the CSI 300 index, rising by 2.97% compared to the index's 1.65% increase, reflecting a revaluation of the innovative drug industry [14] - A notable BD transaction occurred on January 30, 2026, when CSPC Pharmaceutical Group signed a collaboration and licensing agreement with AstraZeneca, involving a $1.2 billion upfront payment and potential milestone payments totaling up to $35 billion for development and $138 billion for sales [15][16] - This transaction exemplifies a platform-based approach, including not only the clinical-stage product SYH2082 but also three preclinical products and four new collaboration projects leveraging CSPC's proprietary technologies [15][16] Potential BD Target Value Identification and Screening Logic - Identifying potential BD targets should focus on differentiated technological barriers, such as the proprietary ADC technology of Kelun-Biotech, which has shown promising clinical data for international licensing [19] - The quality of proof of concept (POC) data is crucial, as seen with Innovent Biologics' IBI363, which has demonstrated efficacy in challenging tumor types, indicating significant commercial potential [19][20] - Global clinical demand and competitive landscape for indications are important, with companies like 3SBio and Diligent Pharma showing strong potential in weight management and oncology, respectively, enhancing their market entry opportunities [20] Conclusion - The Chinese innovative pharmaceutical industry is entering an "Innovation 3.0 era," characterized by a shift from single product licensing to systematic technology platform outputs and deep strategic alliances [21] - The current high activity in BD transactions reflects the industry's strengthening capabilities and serves as a catalyst for value reassessment, positioning companies with technological advantages and high-quality clinical data for significant roles in the global pharmaceutical landscape [21]

Summary of Key Points from the Conference Call Industry Overview - The focus is on the **Pharmaceutical (Pharma)** and **Biopharmaceutical/Biotech** sectors, highlighting companies with potential for value re-evaluation and those entering a performance ramp-up phase [1][2]. Core Insights and Arguments 1. **Value Re-evaluation of Pharma Companies**: - There is a recommendation to further support Pharma companies that have the potential for value re-evaluation, particularly emphasizing key marginal changes. The BD (Business Development) revenue for Pharma is expected to normalize, which will drive an upward shift in the valuation framework [1][2]. 2. **Performance Ramp-up in Biopharma/Biotech**: - Continuous recommendation for Biopharma/Biotech companies that are entering a performance ramp-up phase and have pipelines that are consistently delivering results. The expectation is that by 2026, leading Biopharma/Biotech companies will enter a period of accelerated performance [2]. 3. **Key Marginal Changes**: - The core marginal change driving the value re-evaluation logic for Pharma companies is the normalization of BD revenue. This is supported by two main factors: - Leading Pharma companies have a more comprehensive technology platform and pipeline layout, enhancing their ability to continuously produce BD assets [2]. - External transactions are evolving from sporadic single-asset licensing to a more platform-based and series-based licensing model, making upfront payments, milestones, and revenue sharing more replicable and predictable. Recent collaborations, such as the partnership between **Shiyao** and **AstraZeneca** for a long-acting weight loss drug (total package of $18.5 billion) and **Innovent** with **Eli Lilly** in oncology and immunology (total package of $8.9 billion), exemplify this trend [2]. Recommendations - Specific companies recommended for investment include: - **Hengrui Medicine** - **Hansoh Pharmaceutical** - **Shiyao Group** (new addition in February) - **China National Pharmaceutical Group** - **Sinopharm** (new addition in February) - **Haisco** [2]. Additional Important Insights - The oncology, metabolism, and autoimmune sectors are expected to see a concentration of critical data releases. The integration of new technology platforms such as small nucleic acids, bispecific/trispecific antibodies, next-generation ADCs, and PROTAC/molecular glue is anticipated to provide significant valuation elasticity for leading companies at key data points, potentially opening up overseas BD opportunities [3].

Summary of Key Points from Conference Call Industry Overview - The conference call discusses the global business development (BD) activities in the pharmaceutical sector during the Chinese New Year period from February 13 to February 23, 2026, highlighting a total of 18 BD transactions globally [1] Core Insights and Arguments - **Key Transactions**: - Qinhai Bio licensed its MAT2A inhibitor (GH31), which has received IND approval in China and the US and is currently in Phase I clinical trials, to Gilead. Qinhai will receive an upfront payment of $80 million, $1.45 billion in milestone payments, and a tiered double-digit percentage royalty based on net sales [1] - Other notable transactions include: - Novartis partnered with Unnatural Products to develop macrocyclic peptide drugs, focusing on cardiovascular applications, with Unnatural Products receiving an upfront payment of $100 million and potential milestone payments of $1.7 billion [1] - Eli Lilly acquired global rights for the IL6 monoclonal antibody clazakizumab from CSL for all indications except end-stage renal disease, with CSL receiving an upfront payment of $100 million [1] - Merck collaborated with Mayo Clinic to integrate clinical and genomic data, focusing on early research translation in inflammatory bowel disease, skin diseases, and neurology [1] - **Year-to-Date Transactions**: - From January 1 to February 23, 2026, there have been 36 BD transactions involving Chinese companies, with 13 of these transactions involving multinational corporations (MNCs) [1] Additional Important Insights - **Comparison with Previous Year**: - In comparison, there were 26 BD transactions during the same period in 2025, with only 3 involving MNCs [2] - **Future Outlook**: - The analysis indicates that MNCs have increased their focus on Chinese BD teams and asset searches since the second half of 2025, suggesting a positive outlook for more BD transactions involving Chinese assets and MNCs in 2026 [2]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]